Bristol-Myers ends hepatitis C drug development

August 24, 2012

(AP)—Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.

The New York company said Thursday that it decided to discontinue development of the drug, labeled BMS-986094, in the interest of .

The patient's prompted Bristol-Myers to voluntarily suspend a mid-stage study of the drug on Aug 1. The U.S. subsequently placed the drug on a clinical hold.

"The decision to halt development of BMS-986094 has been guided by our overriding interest in protecting patients," Elliott Sigal, Bristol-Myers' chief scientific officer, said in a statement.

Nine patients, including the one who died, were hospitalized. Two remain under hospital care, the company said.

Bristol-Myers said it hasn't definitively established what caused patients to become ill, but identified heart and kidney toxicity as a key factor.

The company said it is working with the FDA to monitor the patients involved in the study. It also said it would continue to investigate the potential cause of the drug's toxicity.

can prove fatal to experimental drugs. The FDA has been focusing more on those risks since & Co. took its painkiller Vioxx off the market several years ago after a study showed the drug doubled the risk of heart attack or stroke.

Bristol Myers has been pushing to become a player in the drug market, which is expected to grow as baby boomers get older.

The discontinued drug was one of two main potential hepatitis C treatments from Bristol-Myers that investors are focused on. The other is a compound labeled daclatasvir that has started late-stage testing, the last step before drugmakers submit a product to regulators for approval.

Bristol-Myers acquired BMS-986094 and some other potential treatments as part of a $2.5 billion acquisition of drug developer Inhibitex Inc. it completed earlier this year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts say the market for treatments is potentially lucrative for drugmakers. More people are expected to be diagnosed with the tough-to-treat disease as the baby boomer generation ages.

After a two-decade drought, the first two new hepatitis C drugs were approved last year: Victrelis from Merck & Co. and Incivek from Vertex Pharmaceuticals Inc. and Johnson & Johnson. Both significantly improve the cure rate over what has long been the standard of care, a mix of injections and pills with nasty, flu-like side effects that takes several months and still doesn't cure many patients.

' shares tumbled when it first announced earlier this month that it was suspending its trial of the C drug. In aftermarket trading Thursday, they added 5 cents to $32.20. The stock ended the regular trading session up 34 cents at $32.15.

Explore further: Bristol-Myers Squibb to buy Inhibitex for $2.5 billion

shares

Related Stories

Bristol-Myers Squibb to buy Inhibitex for $2.5 billion

January 8, 2012
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).

Bristol-Myers to buy diabetes drug maker for $5B

July 1, 2012
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.

FDA questions safety of experimental diabetes drug

July 15, 2011
(AP) -- Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.